Published in Experientia on September 15, 1971
Biology of Trypanosoma cruzi. Annu Rev Microbiol (1973) 4.13
Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg (1987) 2.66
Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc Natl Acad Sci U S A (1996) 2.35
Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol (1976) 2.20
Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol (1982) 2.10
Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother (2000) 1.87
Tissue tropism of different Trypanosoma cruzi strains. J Parasitol (1978) 1.83
Immunity to Trypanosoma cruzi. Adv Parasitol (1980) 1.66
Depletion of T and B lymphocytes during malarial infections. Cell Immunol (1974) 1.65
Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox. Mol Biochem Parasitol (1998) 1.53
American cutaneous leishmaniasis: use of a skin test as a predictor of relapse after treatment. Bull World Health Organ (2000) 1.51
Virus-expressed, recombinant single-chain antibody blocks sporozoite infection of salivary glands in Plasmodium gallinaceum-infected Aedes aegypti. Am J Trop Med Hyg (2000) 1.51
Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin Exp Immunol (1979) 1.44
Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J Med Chem (1978) 1.43
Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's disease. Trans R Soc Trop Med Hyg (1982) 1.41
Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans R Soc Trop Med Hyg (1993) 1.38
Antimalarial activity of crude extracts from Brazilian plants studied in vivo in Plasmodium berghei-infected mice and in vitro against Plasmodium falciparum in culture. Braz J Med Biol Res (1991) 1.36
The in vitro interaction of Trypanosoma cruzi bloodstream forms and mouse peritoneal macrophages. Acta Trop (1978) 1.35
Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc Natl Acad Sci U S A (2001) 1.32
Antiprotozoan and antibacterial activity of 2-nitroimidazole derivatives. Antimicrob Agents Chemother (Bethesda) (1967) 1.28
Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax. Mol Biochem Parasitol (1992) 1.27
A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother (2000) 1.23
Human and mouse sera recognize the same polypeptide associated with immunological resistance to Trypanosoma cruzi infection. Clin Exp Immunol (1985) 1.23
In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother (2000) 1.23
Potential antimalarials from Nigerian plants: a review. J Ethnopharmacol (2010) 1.22
Antimalarial activity of extracts and fractions from Bidens pilosa and other Bidens species (Asteraceae) correlated with the presence of acetylene and flavonoid compounds. J Ethnopharmacol (1997) 1.22
Cross-reactivity between antibodies in the sera of individuals with leishmaniasis, toxoplasmosis, and Chagas' disease and antigens of the blood-stage forms of Plasmodium falciparum determined by indirect immunofluorescence. Am J Trop Med Hyg (1995) 1.21
Presence and formation of codeine and morphine in the rat. Proc Natl Acad Sci U S A (1986) 1.20
Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease. J Clin Lab Anal (1993) 1.16
Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int Immunol (1994) 1.16
Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob Agents Chemother (1998) 1.15
Developmentally regulated infectivity of malaria sporozoites for mosquito salivary glands and the vertebrate host. J Exp Med (1992) 1.14
Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother (2001) 1.14
Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol (1996) 1.14
Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin Diagn Lab Immunol (1995) 1.13
Antimalarial activity of Cinchona-like plants used to treat fever and malaria in Brazil. J Ethnopharmacol (2003) 1.08
Identification of cysteine 354 of beta-tubulin as part of the binding site for the A ring of colchicine. J Biol Chem (1996) 1.08
[Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease]. Rev Soc Bras Med Trop (1994) 1.07
Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease. Med Res Rev (1995) 1.06
Antiplasmodial triterpene from Vernonia brasiliana. Planta Med (1997) 1.05
Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere. Pharmacol Ther (1979) 1.05
Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease. J Clin Microbiol (1995) 1.04
Idiotype stimulation of T lymphocytes from Trypanosoma cruzi-infected patients. J Immunol (1988) 1.02
Transformation of trypomastigote forms of Trypanosoma cruzi into activators of alternative complement pathway by immune IgG fragments. Scand J Immunol (1985) 1.01
Antitumor agents. 199. Three-dimensional quantitative structure-activity relationship study of the colchicine binding site ligands using comparative molecular field analysis. J Med Chem (2000) 1.01
Mapping the binding site of colchicinoids on beta -tubulin. 2-Chloroacetyl-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. J Biol Chem (2000) 1.01
Trypanosoma cruzi genome project: biological characteristics and molecular typing of clone CL Brener. Acta Trop (1997) 1.00
Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol (1991) 1.00
Controlling malaria transmission with genetically-engineered, Plasmodium-resistant mosquitoes: milestones in a model system. Parassitologia (1999) 1.00
Structure of an ether dimer of deoxydihydroqinghaosu, a potential metabolite of the antimalarial arteether. Acta Crystallogr C (1989) 1.00
Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett (1985) 1.00
Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission. Scand J Immunol (2008) 0.99
Multiepitope synthetic peptide and recombinant protein for the detection of antibodies to Trypanosoma cruzi in patients with treated or untreated Chagas' disease. J Infect Dis (2000) 0.99
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. J Med Chem (1999) 0.98
The effects of some immunosuppressive agents in experimental chronic Chagas's disease. Trans R Soc Trop Med Hyg (1971) 0.98
Self and nonself stimulatory molecules induce preferential expansion of CD5+ B cells or activated T cells of chagasic patients, respectively. Scand J Immunol (2000) 0.97
Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas' disease. Infect Immun (1994) 0.97
New evidences of antimalarial activity of Bidens pilosa roots extract correlated with polyacetylene and flavonoids. J Ethnopharmacol (2004) 0.96
A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann Trop Med Parasitol (1982) 0.95
Survey of medicinal plants used as antimalarials in the Amazon. J Ethnopharmacol (1992) 0.94
Differences in the susceptibility of Trypanosoma cruzi strains to active chemotherapeutic agents. Rev Inst Med Trop Sao Paulo (1977) 0.94
[Clinical course of 112 cases of Schistosomiasis mansoni observed after 10 years of living in endemic foci in Minas Gerais]. Rev Inst Med Trop Sao Paulo (1967) 0.94
Cellular immune responses of chagasic patients to antigens derived from different Trypanosoma cruzi strains and clones. Am J Trop Med Hyg (1986) 0.93
N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. Evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem (1990) 0.92
Intraspecific variation in Trypanosoma cruzi: effect of temperature on the intracellular differentiation in tissue culture. J Parasitol (1977) 0.92
Influence of parasite presence on the immunologic profile of peripheral blood mononuclear cells from chagasic patients after specific drug therapy. Parasite Immunol (1996) 0.91
The targets of the lytic antibody response against Trypanosoma cruzi. Parasitol Today (2000) 0.91
Plasmodium gallinaceum: antibodies to circumsporozoite protein prevent sporozoites from invading the salivary glands of Aedes aegypti. Exp Parasitol (1992) 0.91
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics. Acta Neurol Scand Suppl (2000) 0.90
Antibody-dependent cell cytotoxicity against Trypanosoma cruzi is only mediated by protective antibodies. Parasite Immunol (1985) 0.90
Anti-AIDS agents part 41: synthesis and anti-HIV activity of 3',4'-di-o-(-)-camphanoyl-(+)-cis-khellactone (DCK) lactam analogues. Bioorg Med Chem Lett (2000) 0.90
Recent developments in the field of Chagas' disease. Bull World Health Organ (1982) 0.90
Antisporozoite antibodies with protective and nonprotective activities: in vitro and in vivo correlations using Plasmodium gallinaceum, an avian model. J Eukaryot Microbiol (1996) 0.90
Comparative inhibitory effects of various physostigmine analogs against acetyl- and butyrylcholinesterases. J Pharmacol Exp Ther (1989) 0.89
Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Am J Trop Med Hyg (1993) 0.89
Deoxymorphines: role of the phenolic hydroxyl in antinociception and opiate receptor interactions. J Med Chem (1979) 0.89
Selective ther cleavage in the aporphine series. Conversion of (S)-bulbocapnine into (S)-corytuberine and (S)-corydine methyl ether. Helv Chim Acta (1976) 0.89
Persistence of humoral response against sporozoite and blood-stage malaria antigens 7 years after a brief exposure to Plasmodium vivax. J Infect Dis (1998) 0.88
Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. J Med Chem (2001) 0.88
[Cutaneous leishmaniasis in the Metropolitan Region of Belo Horizonte: clinical, laboratorial, therapeutic and prognosis features (1989-1995)]. Rev Soc Bras Med Trop (2001) 0.87
Effect of interferon on the development of Trypanosoma cruzi in tissue culture "vero" cells. Mem Inst Oswaldo Cruz (1980) 0.87
Aspects of early growth of different Trypanosoma cruzi strains in culture medium. J Parasitol (1965) 0.87
[Contribution to the parasitological diagnosis of human Chagas' disease in its chronic phase]. Rev Inst Med Trop Sao Paulo (1967) 0.87
The behavior of slender and stout forms of Trypanosoma cruzi in the blood-stream of normal and immune mice. Ann Trop Med Parasitol (1969) 0.87
Mechanism of acquired immunity induced by "Leptomonas pessoai" against Trypanosoma cruzi in mice. J Protozool (1974) 0.86
Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines. J Med Chem (1990) 0.86
In vitro activity of natural and synthetic naphthoquinones against erythrocytic stages of Plasmodium falciparum. Braz J Med Biol Res (1988) 0.86
Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents. J Med Chem (1997) 0.86
Exacerbation of experimental Trypanosoma cruzi infection in mice by concomitant malaria. J Protozool (1977) 0.86
Hematological changes in mice experimentally infected with Trypanosoma cruzi. Mem Inst Oswaldo Cruz (1983) 0.85
Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade. Clin Exp Immunol (1985) 0.85
Antitubulin effects of derivatives of 3-demethylthiocolchicine, methylthio ethers of natural colchicinoids, and thioketones derived from thiocolchicine. Comparison with colchicinoids. J Med Chem (1990) 0.85
Carbamate analogues of (-)-physostigmine: in vitro inhibition of acetyl- and butyrylcholinesterase. FEBS Lett (1988) 0.85